Syncom Formulations (India) Ltd.
Fundamentals
- Market cap
- ₹1,306 cr
- P/E
- 17.08×
- ROE
- 14.45%
- Debt / equity
- 0.01
- 52-week range
- 10.21 — 20.13
Company snapshot
Syncom Formulations (India) Ltd.
Pharmaceuticals
₹1,347 cr
P/E 17.62×
Latest quarter · Mar 2026
Sales₹135 cr
Net profit₹25 cr
Op. margin+16.3%
EPS₹0.27
Strength & growth
Debt / equity0.01×
Current ratio4.41×
Sales CAGR+10.9%
EPS CAGR+31.9%
The timeline — 2 notes on Syncom Formulations (India) Ltd.
May 2026
- 22 May 26 · 6:54 PM IST Brief Brief · Earnings · Small cap
Syncom's FY26 profit jumped 55%. The filing adds nothing else.
A routine annual filing delivers strong growth but no drivers, no guidance, and no new narrative.
- 22 May 26 · 6:35 PM IST Brief Brief · Earnings · Small cap
Syncom Formulations profit jumps 55% as revenue gains slow
Annual profit hit ₹76 crore on cost management, while fourth-quarter revenue contracted 10%.